Injections or pills for weight loss: what the clinical evidence actually shows

What the trial results say about weight reduction by format

The SURMOUNT-1 trial (2,539 adults with obesity over 72 weeks) showed average body-weight reductions of around 20–21% at the highest tirzepatide dose, published in the New England Journal of Medicine. That figure sits at the top of published GLP-1 evidence. Weekly semaglutide injection (Wegovy 2.4mg) produced around 15% in STEP 1 over 68 weeks.

Oral semaglutide (Wegovy tablets) was approved in the UK in June 2026, the first oral GLP-1 licensed here for weight management. The OASIS 4 trial (307 adults, 64 weeks, with lifestyle support) reported around 13.6% average weight loss against placebo. Among participants who stayed fully adherent throughout the trial, that figure rose to about 16.6%. One common misconception is that the pill is simply a weaker version of the injection; it is more accurate to say the formats produce different mean outcomes, and for some people the convenience of a tablet changes adherence patterns enough to matter.

For a broader look at how the injectable options compare with each other, the which injection is better for weight loss page covers that ground in detail. If you are weighing the two formats side by side more generally, our pills vs injections comparison sets out the key data points cleanly.

Why the absorption route changes more than just convenience

Subcutaneous injections deliver medicine directly into tissue; absorption is consistent and largely independent of what you ate or when. That consistency is part of why injection trials tend to show higher mean results.

Oral semaglutide is co-formulated with an absorption enhancer called SNAC, which allows the tablet to cross the stomach lining, but only when conditions are right. The tablet must be taken first thing in the morning on an empty stomach with a small amount of plain water (up to about 120ml), then nothing else, including coffee or other medicines, for at least 30 minutes. Miss that window and absorption falls sharply. The NHS semaglutide page covers these requirements in plain language. Injections carry their own demands: refrigerated storage between 2°C and 8°C, rotating injection sites (abdomen, thigh or upper arm), and for some people an initial hesitation about self-injecting that fades quickly in practice.

Storage for the tablet is straightforward, room temperature, no cold chain. For people who travel frequently or whose fridge access is unreliable, that matters. If you are curious about how injections fit into travel and daily routines, the weight-loss injection guide has practical detail on storage and administration.

Eligibility, titration and what the prescriber weighs up

Both formats share similar licensed eligibility thresholds: adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK guidance. Mounjaro titrates from 2.5mg upward in roughly four-week steps; Wegovy tablets start at 1.5mg and escalate through 4mg and 9mg to the 25mg maintenance dose, again with at least a month at each level. The starter dose for any format exists to give your system time to adjust, not to produce the headline results.

The prescriber's job is to weigh your medical history, any medicines you already take, your daily routine and your preferences. Oral contraceptive users, for instance, are advised to add a barrier method during the first four weeks of tirzepatide and for four weeks after each dose increase, because gastric slowing can reduce pill absorption. That kind of interaction detail shapes the clinical decision. Our treatment consultation page explains how that process works at nume, where a GPhC-registered prescriber reviews every case personally.

For people specifically curious about the tablet format's profile, a direct tablets-versus-injections comparison is worth reading before your consultation. Those who want to understand the injection side in more depth will find the weight-loss injections overview a useful starting point.

Side effects and what they mean for choosing a format

Both injection and oral formats share a GI-led side-effect profile: nausea, loose stools, constipation, indigestion and, less commonly, vomiting. These tend to peak in the days following a dose change and settle for most people within one to two weeks. In the OASIS 4 trial, around 74% of oral semaglutide participants reported gastrointestinal effects, compared with 42% on placebo, generally mild to moderate and transient. Injection trials show a broadly similar pattern, though rates vary by dose and individual.

Pancreatitis is a less common but serious concern across GLP-1 medicines. In January 2026 the MHRA issued a Drug Safety Update highlighting acute pancreatitis as a known infrequent risk: severe, persistent stomach pain that may radiate to the back is a reason to seek urgent medical attention. The Yellow Card scheme allows patients to report suspected side effects directly to the MHRA, and doing so genuinely helps build the safety picture for these medicines. Pregnancy, breastfeeding and trying to conceive are all reasons neither format is recommended; the same applies to anyone under 18. These considerations apply equally regardless of format and are part of every prescriber consultation. If you have a specific question about suitability for your situation, this page on injections versus tablets addresses some of the more nuanced factors.